New drug combination for previously treated multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether a new drug called cevostamab, combined with two existing myeloma drugs (pomalidomide and dexamethasone), works better than standard treatment for people whose myeloma has returned or stopped responding to prior therapy. You would receive this combination to see if it helps control your disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma (a blood cancer affecting plasma cells) according to standard medical criteria
- You have received 1–3 previous treatment regimens, each including either an anti-CD38 drug or lenalidomide for at least two cycles
- You have measurable disease (doctors can detect and measure your myeloma) during screening
- Your overall health status allows you to be fairly active, with little or no bed rest (ECOG score 0–1, or score 2 only if caused by myeloma pain)
- You do not have plasma cell leukemia or excessively high circulating plasma cells in your blood
- You do not have gastrointestinal problems that would prevent your body from absorbing oral medications, CNS (brain or spinal cord) disease, or non-secretory myeloma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called cevostamab for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
This trial tests a new drug, cevostamab, combined with two standard medicines (pomalidomide and dexamethasone) for people with multiple myeloma who have already had CAR T-cell therapy. It aims to see if this combination can help control the cancer better.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This trial tests a new combination of four drugs for people with high-risk multiple myeloma that has come back or did not respond to initial treatment. The goal is to see if this combination is safe and effective.
This trial is testing a new combination of drugs for people with untreated multiple myeloma who are healthy enough for a stem cell transplant. It aims to see if the treatment is safe and effective.
This trial tests a new combination of drugs for people with multiple myeloma whose cancer did not respond to or returned after one prior treatment with lenalidomide. The goal is to see if this combination is safe and effective.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.